PeptiDream Inc (PPTDF)
13.11
+3.61
(+38.00%)
USD |
OTCM |
Apr 30, 16:00
PeptiDream Enterprise Value: 1.718B for April 30, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 30, 2024 | 1.718B |
| April 29, 2024 | 1.250B |
| April 26, 2024 | 1.250B |
| April 25, 2024 | 1.250B |
| April 24, 2024 | 1.250B |
| April 23, 2024 | 1.250B |
| April 22, 2024 | 1.250B |
| April 19, 2024 | 1.250B |
| April 18, 2024 | 1.250B |
| April 17, 2024 | 1.250B |
| April 16, 2024 | 1.250B |
| April 15, 2024 | 1.250B |
| April 12, 2024 | 1.250B |
| April 11, 2024 | 1.250B |
| April 10, 2024 | 1.250B |
| April 09, 2024 | 1.250B |
| April 08, 2024 | 1.250B |
| April 05, 2024 | 1.250B |
| April 04, 2024 | 1.250B |
| April 03, 2024 | 1.250B |
| April 02, 2024 | 1.250B |
| April 01, 2024 | 1.250B |
| March 28, 2024 | 1.250B |
| March 27, 2024 | 1.250B |
| March 26, 2024 | 1.250B |
| Date | Value |
|---|---|
| March 25, 2024 | 1.250B |
| March 22, 2024 | 1.250B |
| March 21, 2024 | 1.250B |
| March 20, 2024 | 1.250B |
| March 19, 2024 | 1.250B |
| March 18, 2024 | 1.250B |
| March 15, 2024 | 1.250B |
| March 14, 2024 | 1.250B |
| March 13, 2024 | 1.250B |
| March 12, 2024 | 1.250B |
| March 11, 2024 | 1.250B |
| March 08, 2024 | 1.250B |
| March 07, 2024 | 1.250B |
| March 06, 2024 | 1.129B |
| March 05, 2024 | 1.129B |
| March 04, 2024 | 1.129B |
| March 01, 2024 | 1.129B |
| February 29, 2024 | 1.129B |
| February 28, 2024 | 1.129B |
| February 27, 2024 | 1.129B |
| February 26, 2024 | 1.129B |
| February 23, 2024 | 1.129B |
| February 22, 2024 | 1.129B |
| February 21, 2024 | 1.129B |
| February 20, 2024 | 1.129B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
996.42M
Minimum
Oct 31 2023
7.515B
Maximum
Feb 11 2021
3.639B
Average
2.930B
Median
Nov 12 2021
Enterprise Value Benchmarks
| Takeda Pharmaceutical Co Ltd | 71.87B |
| Nxera Pharma Co Ltd | 972.42M |
| Stemcell Holdings Inc | -- |
| Healios KK | 73.17M |
| AnGes Inc | 37.97M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.424M |
| Revenue (Quarterly) | 41.78M |
| Total Expenses (Quarterly) | 41.64M |
| EPS Diluted (Quarterly) | -0.0263 |
| Gross Profit Margin (Quarterly) | 48.45% |
| Profit Margin (Quarterly) | -8.20% |
| Earnings Yield | 1.22% |
| Operating Earnings Yield | 2.73% |
| Normalized Earnings Yield | 1.220 |